TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05734066: A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2D), and Efficacy of Lurbinectedin Monotherapy in Pediatric Participants With Previously Treated Soli

Sponsor: Jazz Pharmaceuticals · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 60 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$2,081,310

Rescue Site Savings

+$1,374,450

Unlock Full NCT05734066 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05734066 Rescue Dossier →